Login / Signup

Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.

David FoxTu My ToArpamas SeetasithAnisha M PatelSusan T Iannaccone
Published in: Advances in therapy (2022)
The findings suggest that adherence and persistence to nusinersen treatment appear low. Demographic (age ≥ 18 years) and clinical factors (no spinal complications) may contribute to nusinersen treatment discontinuation. Future research should explore possible reasons for low adherence and persistence to nusinersen treatment, such as clinical or logistical factors, patient preferences, and payer restrictions.
Keyphrases
  • type diabetes
  • spinal cord
  • case report
  • metabolic syndrome
  • adipose tissue
  • glycemic control
  • health insurance